Stryker (NYSE:SYK) Downgraded to Hold Rating by StockNews.com

Stryker (NYSE:SYK) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

A number of other research analysts have also recently weighed in on SYK. Stifel Nicolaus lifted their price target on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler reaffirmed an “overweight” rating and set a $420.00 price target (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. JMP Securities restated a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Finally, Citigroup raised their target price on Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $419.37.

Stryker Stock Up 0.1 %

Shares of NYSE SYK opened at $390.90 on Thursday. Stryker has a 52-week low of $314.93 and a 52-week high of $406.19. The firm has a fifty day moving average of $376.56 and a 200-day moving average of $362.38. The stock has a market capitalization of $149.02 billion, a PE ratio of 50.37, a P/E/G ratio of 2.68 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same period in the previous year, the company earned $3.46 EPS. On average, analysts anticipate that Stryker will post 13.53 EPS for the current year.

Insider Buying and Selling at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.90% of the stock is currently owned by insiders.

Institutional Trading of Stryker

A number of institutional investors and hedge funds have recently made changes to their positions in SYK. Zhang Financial LLC lifted its stake in Stryker by 55.0% in the fourth quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company’s stock valued at $41,366,000 after buying an additional 40,784 shares during the last quarter. Dale Q Rice Investment Management Ltd acquired a new position in Stryker during the 4th quarter valued at about $587,000. Berkshire Bank grew its position in Stryker by 13.8% in the 4th quarter. Berkshire Bank now owns 8,489 shares of the medical technology company’s stock worth $3,056,000 after purchasing an additional 1,030 shares during the last quarter. PFW Advisors LLC acquired a new stake in shares of Stryker in the fourth quarter valued at approximately $1,350,000. Finally, Traynor Capital Management Inc. bought a new stake in shares of Stryker during the fourth quarter valued at approximately $324,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.